. . "RIV/00216224:14110/02:00007785" . . "dendritic cells; multiple myeloma; immunotherapy"@en . "Monitorov\u00E1n\u00ED dendritick\u00FDch bun\u011Bk a jejich podtyp\u016F v pr\u016Fb\u011Bhu l\u00E9\u010Dby nemocn\u00FDch s mnoho\u010Detn\u00FDm myelomem."@cs . . . "Kov\u00E1\u0159ov\u00E1, Lucie" . "V\u00E1\u0148ov\u00E1, Pavl\u00EDna" . . . "Monitorov\u00E1n\u00ED dendritick\u00FDch bun\u011Bk a jejich podtyp\u016F v pr\u016Fb\u011Bhu l\u00E9\u010Dby nemocn\u00FDch s mnoho\u010Detn\u00FDm myelomem." . "2"^^ . "211-215" . "0862-495X" . . "Adam, Z." . . "ro\u010D. 15" . . "Monitorov\u00E1n\u00ED dendritick\u00FDch bun\u011Bk a jejich podtyp\u016F v pr\u016Fb\u011Bhu l\u00E9\u010Dby nemocn\u00FDch s mnoho\u010Detn\u00FDm myelomem."@cs . "V\u00FDchodiska: V t\u00E9to studii bylo hodnoceno zastoupen\u00ED subtyp\u016F dendritick\u00FDch bun\u011Bk (DB) - DB1, DB2 - pacient\u016F s mnoho\u010Detn\u00FDm myelomem (MM) p\u0159ed po\u010D\u00E1tkem l\u00E9\u010Dby a v jej\u00EDm pr\u016Fb\u011Bhu. Metody a v\u00FDsledky : Flowcytometrick\u00E9 stanoven\u00ED po\u010Dtu DB perifern\u00ED krve bylo prov\u00E1d\u011Bno na z\u00E1klad\u011B pozitivn\u00ED exprese povrchov\u00FDch antigen\u016F - CD83 spole\u010Dn\u011B s HLA-DR, CD11c a CD123. Kontroln\u00ED skupina zdrav\u00FDch jedinc\u016F (n = 15; pr\u016Fm\u011Br 0,62+/-0,06% CD83+ bun\u011Bk; pom\u011Br DB1/DB2 = 2,5) nevykazovala statisticky v\u00FDznamn\u00FD rozd\u00EDl p\u0159i srovn\u00E1n\u00ED se vstupn\u00EDm hodnocen\u00EDm pacient\u016F p\u0159ed l\u00E9\u010Dbou (n = 15; 0,59+/-0,13% CD83+ bun\u011Bk; DB1/DB2 = 2,17). U l\u00E9\u010Den\u00FDch pacient\u016F (n = 10) do\u0161lo po induk\u010Dn\u00ED l\u00E9\u010Db\u011B VAD (vincristin + adriamycin + dexamethazon) k n\u00E1r\u016Fstu celkov\u00E9ho po\u010Dtu DB (0,84+/-0,4%; DB1/DB2 = 1,59) ve srovn\u00E1n\u00ED s po\u010D\u00E1te\u010Dn\u00EDmi hodnotami, po aplikaci G-CSF po\u010Det DB poklesl (0,66+/-0,6%; DB1/DB2 = 3,71). Nejni\u017E\u0161\u00EDch hodnot celkov\u00E9ho po\u010Dtu DB bylo dosa\u017Eeno v afer\u00E9zn\u00EDm produktu (0,36+/-0,2%; DB1/DB2 = 4,75). Aplikace GM-CSF vyvolala zv\u00FD\u0161en\u00ED po\u010Dtu DB (0,56+/-0,3%" . "Monitorov\u00E1n\u00ED dendritick\u00FDch bun\u011Bk a jejich podtyp\u016F v pr\u016Fb\u011Bhu l\u00E9\u010Dby nemocn\u00FDch s mnoho\u010Detn\u00FDm myelomem." . "9"^^ . "Musilov\u00E1, Romana" . "Background: In this study was evaluated the proportion of dendritic cells (DC) subsets-DC1, DC2-in peripheral blood of patients with multiple myeloma (MM) before and during treatment. Methods and results: Flowcytometric determination of DC in the peripheral blood was based on the positive expression of surface antigens - CD83 in combination with HLA-DR, CD11c and CD123. No significant differencies were found in initial values between the group of healthy volunteers (n = 15; mean count of CD83+ cells was 0,62+/-0,06%; ratio DC1/DC2 = 2,5) and the group of patients before treatment (n = 15; 0,59+/-0,13% CD83+; DC1/DC2 = 2,17). In the group of patients (n = 10), after induction treatment with VAD regimen (vincristin, adriamycin, dexamethason), mean percentage of DC (0,84+/-0,4% CD83+ cells; DC1/DC2 = 1,59) was higher than initial values. Administration of the G-CSF reduced the total DC numbers (0,66+/-0,6%, DC1/DC2 = 3,71). The lowest total DC counts were in the apheresis products (0,36+/-0,2%; DC1/DC2 ="@en . "Monitoring of dendritic cells and their subsets during treatment in multiple myeloma."@en . "CZ - \u010Cesk\u00E1 republika" . "[CACAB3C3832A]" . "B\u00FCchler, Tom\u00E1\u0161" . "Monitoring of dendritic cells and their subsets during treatment in multiple myeloma."@en . . . "Svobodn\u00EDk, A." . . "V\u00FDchodiska: V t\u00E9to studii bylo hodnoceno zastoupen\u00ED subtyp\u016F dendritick\u00FDch bun\u011Bk (DB) - DB1, DB2 - pacient\u016F s mnoho\u010Detn\u00FDm myelomem (MM) p\u0159ed po\u010D\u00E1tkem l\u00E9\u010Dby a v jej\u00EDm pr\u016Fb\u011Bhu. Metody a v\u00FDsledky : Flowcytometrick\u00E9 stanoven\u00ED po\u010Dtu DB perifern\u00ED krve bylo prov\u00E1d\u011Bno na z\u00E1klad\u011B pozitivn\u00ED exprese povrchov\u00FDch antigen\u016F - CD83 spole\u010Dn\u011B s HLA-DR, CD11c a CD123. Kontroln\u00ED skupina zdrav\u00FDch jedinc\u016F (n = 15; pr\u016Fm\u011Br 0,62+/-0,06% CD83+ bun\u011Bk; pom\u011Br DB1/DB2 = 2,5) nevykazovala statisticky v\u00FDznamn\u00FD rozd\u00EDl p\u0159i srovn\u00E1n\u00ED se vstupn\u00EDm hodnocen\u00EDm pacient\u016F p\u0159ed l\u00E9\u010Dbou (n = 15; 0,59+/-0,13% CD83+ bun\u011Bk; DB1/DB2 = 2,17). U l\u00E9\u010Den\u00FDch pacient\u016F (n = 10) do\u0161lo po induk\u010Dn\u00ED l\u00E9\u010Db\u011B VAD (vincristin + adriamycin + dexamethazon) k n\u00E1r\u016Fstu celkov\u00E9ho po\u010Dtu DB (0,84+/-0,4%; DB1/DB2 = 1,59) ve srovn\u00E1n\u00ED s po\u010D\u00E1te\u010Dn\u00EDmi hodnotami, po aplikaci G-CSF po\u010Det DB poklesl (0,66+/-0,6%; DB1/DB2 = 3,71). Nejni\u017E\u0161\u00EDch hodnot celkov\u00E9ho po\u010Dtu DB bylo dosa\u017Eeno v afer\u00E9zn\u00EDm produktu (0,36+/-0,2%; DB1/DB2 = 4,75). Aplikace GM-CSF vyvolala zv\u00FD\u0161en\u00ED po\u010Dtu DB (0,56+/-0,3%"@cs . . "H\u00E1jek, Roman" . "6"^^ . "P(GA301/00/0405)" . "14110" . "654217" . "Klabusay, M." . "RIV/00216224:14110/02:00007785!RIV08-GA0-14110___" . "6" . . "Klinick\u00E1 onkologie" . . "Krej\u010D\u00ED, M." .